Table 1.

FDA-approved kinase inhibitors.

Compound	Kinase target	Clinical Use
Desatinib	multikinase	CML, ALL
Erlotinib	EGFR
Gefitinib	EGFR
Imatinib	BCR-Abl	CML Gastrointestinal Stromal Tumors Hypereosinophilic syndrome
Lapatinib	EGFR, Erb2	Breast cancer, other tumors
Lestaurinib	FLT3	AML
Sorafenib	multikinase	Renal cell cancer

Abbreviations: ALL – acute lymphocytic leukemia, CML – chronic myelogenous leukemia, EGFR – epidermal growth factor receptor, Erb2 – FLT3 – Fms-like tyrosine kinase 3,